47757643-A7B2-4782-8DAF-AE56BE8777D2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.077529566360052
- age_years
- 52
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 28B7B2FC-8270-42E3-95ED-4CC4F0979EE9 | — | — | 0.857 |
| 2 | R205 | — | — | 0.852 |
| 3 | SRR934967 | — | — | 0.838 |
| 4 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.822 |
| 5 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.817 |
| 6 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.811 |
| 7 | E2C7E2B8-BC9B-476C-A705-CBBCA51F7C26 | — | — | 0.808 |
| 8 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.807 |
| 9 | TCGA-92-7341-01A-31R-2045-07 | — | cohortSQ2 | 0.802 |
| 10 | SRR12696773 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.394 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.379 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.378 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.378 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.361 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.355 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.346 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.343 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.339 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.324 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.311 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.307 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.293 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.287 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.282 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.234 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.227 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.193 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |